Asset sale Completed

Servier acquisition of Sevasemten and Edgewise muscular dystrophy business

US$1.6bn consideration

Announced 1 Jun 2026

Advisers

Sevasemten and Edgewise muscular dystrophy business

Target

Financial adviser

Servier

Acquirer

Not disclosed

Other advisers

Financial adviser
Target
Sevasemten and Edgewise muscular dystrophy business
Acquirer
Servier
Seller
Edgewise Therapeutics
Target based in
United States
Buyer based in
France
Seller based in
United States
Completed
13 Jul 2026
Sector
Biotech
Tags
Biotech, Drug Development, Rare Disease

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.